Introduction
A molecular understanding of leukemogenesis has presented a new paradigm for the development of chemotherapy. 1 Compounds such as all-trans retinoic acid and tyrosine kinase inhibitor have achieved a breakthrough in the treatment of leukemia. 2, 3 They target fusion gene products, PML-RAR␣ and Bcr-Abl, respectively, and are selectively effective against leukemia cells. The issue now is how to extend the frontier of mechanism-based therapies for leukemia. Although various molecules associated with signal transduction, the cell cycle and apoptosis have been investigated as targets for therapy, these approaches do not necessarily verify selectivity to leukemia cells.
FLT3 is a class III receptor tyrosine kinase family and plays important roles in regulating the proliferation, differentiation, and survival of hematopoietic cells. 4, 5 Functional FLT3 is frequently expressed in human acute myeloid leukemia (AML) cells. 6 Furthermore, 20% of patients with AML have an internal tandem duplication (ITD) of the FLT3 juxtamembrane (JM) domain, 7, 8 which is associated with leukocytosis and a poor prognosis. [9] [10] [11] The ITD causes constitutive dimerization and Tyr phosphorylation of the products, 12 and activates MAPK and STAT5 pathways. 13, 14 Tandemly duplicated FLT3 (TDFLT3) abrogated the IL-3 dependency of murine myeloid cell lines. We reported that growth inhibition of TDFLT3- transformed 32D (TDFLT3/32D) could be used as an index for candidate compounds for a drug that specifically treats leukemia. 15 Herbimycin A (HA), formerly known as a tyrosine kinase inhibitor, 16, 17 was chosen because of its selective cytotoxicity to TDFLT3/32D. 15 Appropriate concentrations of HA suppressed the constitutive tyrosine phosphorylation of TDFLT3 but not that of the ligand-stimulated wild-type FLT3 (WtFLT3), although the mechanism is unknown.
HA and geldanamycin (GA), which are benzoquinone ansamycins, have been developed as anti-tumor agents, because they inhibit the growth of transformed cells and have inhibitory activity against oncogenic tyrosine kinases such as v-Src and ErbB-2.
18-20 Importantly, HA and GA had no direct effect on tyrosine kinase activity in an immune complex assay in vitro. 21 A solid phase-immobilized GA derivative and affinity experiments revealed that the molecular target of GA is Hsp90. 22 According to crystal structure analysis, GA directly binds inside the N-terminal pocket of Hsp90. 23 The cellular activity of GA and HA thus results from disruption of the Hsp90-dependent function of the client proteins. 24, 25 The inhibition of Hsp90 function leads to misfolding or rapid degradation of the client proteins, although the molecular mechanism remains unclear. To date, several authentic proteins such as steroid receptors and Raf-1, 22 ,26 viral proteins such as v-Src, 18 and chimeric proteins such as Bcr-Abl reportedly bind with Hsp90, [27] [28] [29] all of which are targeted by Hsp90 inhibitors. However, there has been no study on the association between FLT3 and Hsp90.
In this study, we observed that HA caused apoptosis of TDFLT3-transformed cells but not of IL3-stimulated 32D cells or of FL-stimulated 32D cells. We investigated the mechanism underlying the selective cytotoxicity of HA, a Hsp90 inhibitor, by examining the molecular association between FLT3 and Hsp90.
Materials and methods

Agents
HA and radicicol were purchased from Sigma-Aldrich (St Louis, MO, USA). They were dissolved in dimethyl sulfoxide (DMSO) at appropriate concentrations and stored at −20°C until use. Recombinant murine IL3 was a generous gift from Kirin Brewery (Tokyo, Japan). Recombinant human FLT3 ligand (FL) was purchased from R&D Systems (Minneapolis, MN, USA).
Cell lines
The murine IL3-dependent myeloid cell line, 32D, was obtained from the RIKEN cell bank (Tsukuba, Japan) and maintained in RPMI1640 containing 10% fetal calf serum and 1 ng/ml murine IL3. Tandemly duplicated and wild-type FLT3-transfected 32D cell lines (TDFLT3/32D and WtFLT3/32D) were described previously. 13, 15, 30 HL60 cell line was also from the RIKEN cell bank, and MOLM13 cell line was provided by Y Matsuo (Fujisaki Cell Center, Okayama, Japan). The former was negative for the FLT3 mutation, whereas the latter harbors ITD of the FLT3 gene. 8 
Growth inhibition assay
Each cell line (2 × 10 5 /ml) was seeded in 24-well culture dishes. After overnight culture, Hsp90 inhibitors were added at various concentrations in triplicate. Viable cells were counted using the trypan blue exclusion assay after 48 h culture. IC 50 was defined as the concentration of compound, which decreased the cell proliferation to 50%, compared with each untreated control.
Determination of apoptosis
For DNA histograms, cells were washed with phosphatebuffered saline (PBS) and re-suspended in PBS containing 0.2% Triton X-100 and 50 g/ml propidium iodide (PI; Sigma Chemical, St Louis, MO, USA). Then, the specimens were quantified by flow cytometry on a FACScan (Becton Dickinson, San Jose, CA, USA). To detect the early stage of apoptosis, an Annexin-V-FIUOS Staining Kit (Boehringer Mannheim, Mannheim, Germany) was used according to the manufacturer's instructions.
Antibodies
Rabbit anti-phospho MAPK, anti-MAPK, anti-phospho Akt and anti-Akt antibodies were obtained from New England Biolabs (Beverly, MA, USA). Rabbit anti-human FLT3 antibody and anti-STAT5a antibody were purchased from Santa Cruz Biotecnology (Santa Cruz, CA, USA). Mouse anti-Hsp90 monoclonal antibody and anti-STAT5a antibody were from Transduction Laboratories (Lexington, KY, USA). Murine antiphosphotyrosine antibody 4G10 were from Upstate Biotechnology (Lake Placid, NY, USA). Mouse anti-Actin monoclonal antibody was from Boehringer Mannheim.
Immunoprecipitation and immunoblot analysis
After the treatment with HA, cells were washed twice with ice-cold PBS, and were lysed in lysis buffer: 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 50 mM NaF, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM Na 3 VO 4 and 1 mM phenylmethylsulfonyl fluoride (PMSF). After incubation for 1 h at 4°C, lysates were spun at 12 000 g and 4°C for 20 min, and pellets were discarded. A portion of the lysed samples was immunoprecipitated with each antibody and protein G sepharose (Amersham Pharmacia Biotech, Uppsala, Sweden). The precipitated or non-precipitated samples were separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and electroblotted on to Immobilon PVDF membranes (Millipore, Bedford, MA, USA). The membranes were blocked overnight at 4°C in 1% blocking reagent (Boehringer Mannheim) in 0.1 M maleic acid and 0.15 M NaCl, pH 7.5, and incubated with antibodies for immuno-detection for 1 h. HRP-labeled goat anti-mouse and rabbit IgG antibody (Amersham Pharmacia) for 1 h and ECL chemiluminescent reagents (Amersham Pharmacia) were used for detection of the signals.
Results
Hsp90 inhibitors induced apoptosis in TDFLT3-transformed leukemia cell lines
Treatment of TDFLT3/32D cells with HA increased the annexin V-positive and PI-negative fraction from 2.3% to 20.5% within 12 h (Figure 1a ) and decreased the mitochondrial membrane potential (data not shown), indicating induction of apoptosis by HA. In DNA histograms (Figure 1b) , the HA treatment increased the sub-G1 fraction of TDFLT3/32D cells within 24 h but not in IL3-derived or FL-stimulated WtFLT3/32D cells (Figure 1b) .
To study whether Hsp90 inhibitors other than HA have similar selective cytotoxicity, radicicol, which is an oxime derivative which is a structurally unrelated Hsp90 inhibitor, was added to the culture of TDFLT3/32D or IL3-derived 32D cells. The viable cell number after 2 day culture was reduced by 50% (IC 50 ) at 0.015 M and 0.04 M radicicol in TDFLT3/32D and 32D, respectively (Figure 2a ). An FLT3/ITD carrying cell line, MOLM13, was more sensitive to Hsp90 inhibitors than HL60, but the IC 50 of both cell lines were higher than TDFLT3/32D cells (data not shown). The growth inhibitory effect of HA on TDFLT3/32D was rescued by the addition of IL-3 (Figure 2b ).
Dephosphorylation of TDFLT3 by HA
To elucidate whether the induction of apoptosis by HA is mediated by TDFLT3, the expression and phosphorylation status of FLT3 were analyzed. Immunoblot analysis revealed that HA did not change the expression level of FLT3 in WtFLT3/32D and TDFLT3/32D, although at a high concen- Leukemia tration it slightly reduced the level (Figure 3a) . Phosphorylation of WtFLT3 was augmented by the addition of FL, which was poorly inhibited by the HA treatment. TDFLT3 was phosphorylated in an FL-independent manner, and at more than 0.1 M, HA suppressed the phosphorylation remarkably ( Figure 3a) . Radicicol had similar dephosphorylation effects on TDFLT3 (data not shown). These findings indicated that the phosphorylation of TDFLT3 was more sensitively inhibited by Hsp90 inhibitors than WtFLT3.
The downstream phosphorylation status in TDFLT3/32D cells treated with HA
We then studied the phosphorylation status of the signal molecules downstream from FLT3, because Hsp90 inhibitors reportedly suppress several signal cascades. In IL3-derived 32D cells, MAPK, Akt and STAT5a were phosphorylated (Figure 3b ). In TDFLT3/32D, they were also phosphorylated ligand independently. In WtFLT3/32D, the former two were ligand dependently phosphorylated (data not shown). HA treatment completely inhibited the phosphorylation of MAPK, Akt and STAT5a in TDFLT3/32D. In 32D, however, the phosphorylation of the signal molecules was not blocked. Thus, the phosphorylation of the downstream molecules was correlated with that of FLT3.
Hsp90 associated with TDFLT3 and was immediately dissociated from it by HA
We studied the molecular interaction between Hsp90 and FLT3. Following HA treatment, the expression level of Hsp90 was not changed (Figure 4 ). Immunoprecipitation and immunoblot analysis showed that TDFLT3 formed a complex with Hsp90, and that HA treatment dissociated TDFLT3 from Hsp90. In contrast, WtFLT3 did not bind Hsp90 regardless of stimulation with FL ( Figure 4 ).
Discussion
In a previous screening, HA was selected as a compound that inhibits the growth of TDFLT3/32D more than that of the parental 32D. 15 Using Cos7 cells, we showed that the constitutive phosphorylation of MtFLT3 was inhibited by HA, but that the ligand-dependent phosphorylation of WtFLT3 was not. In the present study, we confirmed this finding in 32D cells. Furthermore, not only HA but also radicicol had similar cytotoxic effects on TDFLT3/32D, and they inhibited the phosphorylation of mutant FLT3. Radicicol, which was developed as an anti-fungal agent and reversed the tumor phenotype of Srcand Ras-transformed cell lines, also targets Hsp90. 31, 32 We thus speculated that Hsp90 was associated with the selective sensitivity of TDFLT3 to HA, although the interaction between FLT3 and Hsp90 was unknown.
In this study, we showed that TDFLT3 formed a complex with Hsp90, and the two were dissociated by HA. On the other hand, WtFLT3 did not bind with Hsp90 regardless of stimulation with FL. These findings suggest that the molecular interaction between Hsp90 and FLT3 is associated neither
Figure 4
Association of FLT3 with Hsp90. WtFLT3/32D stimulated with or without 50 ng/ml FL for 10 min were analyzed by immunoprecipitation followed by immunoblotting using indicated antibodies. TDFLT3/32D was treated with HA at 0.03, 0.1 and 0.3 M HA for 12 h and was assayed. For detection of Hsp90 expression levels, whole cell lysates were immunoblotted by anti-Hsp90 antibody.
with the authentic kinase activity of FLT3 nor with the dimer formation of FLT3. Furthermore, the expression level of TDFLT3 was not significantly changed by the HA treatment, suggesting that Hsp90 acts as a molecular chaperon to maintain the oncogenic properties rather than to inhibit the degradation of TDFLT3. Hsp90 might be important in preventing the misfolding of TDFLT3, since TDFLT3 has an abnormally elongated JM domain. Recent studies have elucidated that Hsp90 has an important role in the refolding of misfolded cellular proteins that accumulate in response to various stress treatments and presumably upon mutational alteration of proteins. Rutherford and Lindquist 33 recently proposed that Hsp90, by binding to mutated proteins, stabilizes them while masking their phenotypic expression, thus allowing accumulation of multiple silent mutations during evolution. In malignancies, it was recently shown that leukemia-specific Bcr-Abl chimeric protein binds with Hsp90, and that Hsp90 inhibitors are effective in suppressing its function and accelerating its degradation. 27, 28 In this respect, the present study is the second study to show that an oncogenic molecule selectively binds with Hsp90.
It is important to fully understand the biological difference between wild-type and mutant FLT3. As we described previously, FL prevented apoptosis but did not stimulate proliferation in WtFLT3/32D, whereas TDFLT3 completely abrogated the IL3 dependency of 32D. The activation of STAT5a, which was observed in TDFLT3/32D but not in WtFLT3/32D, might account for the difference, because the dominant negative mutant STAT5a was enough for 32D to proliferate. 34 The mechanism of activation of STAT5a by TDFLT3 remains unclear. Hsp90 might be associated with the formation of large immobilized complexes of signal transducing molecules like a scaffolding protein, however further study is required.
In addition to the above function, Hsp90 seems to be involved in the activation of limited but authentic signal molecules including Raf-1. 35 In the present study, HA treatment did not inhibit the phosphorylation of MAPK in WtFLT3/32D stimulated by FL and in 32D stimulated by IL3. Thus, GA might inhibit TDFLT3 at lower concentrations than Raf-1. Another possibility is that MAPK activation is Raf-1 independent in 32D cells and TDFLT3/32D cells. Furthermore, Akt and STAT5a were not dephosphorylated by HA in 32D, suggesting that both pathways were insensitive to Hsp90 inhibitors.
Our initial attempt was a search for a TDFLT3-selective inhibitor, and we found a clue as to how to target TDFLT3. However, the concentration of Hsp90 inhibitors is critical when selectively inhibiting the function of TDFLT3, because Hsp90 is an essential molecule under stressful and physiological conditions. On the other hand, mice in which either FLT3 or FL is knocked out have no obvious phenotype, 36 presumably because the FLT3 signal is redundant to the c-KIT one. 37 Thus we think that FLT3 is a rational target for leukemiaselective therapy without severe side-effects in vivo. Development of a FLT3-specific inhibitor should be continued. Until a specific compound is obtained, Hsp90 might be a promising target for the treatment of AML with TDFLT3. orial Foundation. We thank Dr Oliver Rosnet, Dr Toshio Kitamura and Kirin Brewery Co Ltd for providing us with materials, and M Agr Manabu Ninomiya, Ms Yoko Kudo and Ms Yoko Tagawa for technical and secretarial assistance.
